Novartis
Swiss pharma giant selling patented medicines like Entresto, Kesimpta, and Pluvicto worldwide.
On the record
Checkpoint: Q2 2026 earnings report, first full quarter showing Entresto generic erosion
The call
Novartis is managing a large, scheduled patent cliff with cash and acquisitions while AI-native drugmakers remain years from shipping a rival product.
Novartis makes prescription medicines and has built up deep relationships with hospitals, insurance companies, and regulators over decades, plus factories and patents that take years to replicate. Traditional generic drug makers and new AI-powered competitors could eventually copy or replace some of its drugs, but that typically takes 10+ years. The real test is whether Novartis can launch enough new blockbuster drugs before its top three medicines lose patent protection in 2026, and whether U.S. price controls squeeze its profits too hard.
Why
01
AI pressure: Isomorphic Labs and AI-native drug-discovery startups. No AI-designed drug has taken approved-market share yet; Novartis itself uses AI internally to speed its own discovery pipeline. Could AI do the core job? Unlikely.
02
Bigger players: Generic manufacturers challenging Entresto patents. A June 2026 court ruling let generic makers begin selling Entresto copies, opening the biggest single revenue leak in the 2026 patent cliff. Could a giant copy it? No, they are blocked.
03
What protects it. Global regulatory approvals, patent estates, payer contracts, and a pipeline refreshed by the Avidity and Myricx deals.
What would change this call
Additional Entresto Hatch-Waxman rulings or settlements with generic makers within 6 months. Shows how much Entresto volume Novartis will lose to generics.
Q2 2026 earnings (July 21) revenue/margin vs ~$14.16B consensus and 40% core margin. Shows whether new drugs are offsetting the 2026 patent-cliff erosion as guided.
US MFN/TrumpRx pricing rollout effect on Novartis core margin through 2026. Shows whether direct-to-patient pricing compresses margins toward the 25% risk line.
Q2 2026 earnings (July 21) revenue/margin vs ~$14.16B consensus and 40% core margin. Shows whether new drugs are offsetting the 2026 patent-cliff erosion as guided.
US MFN/TrumpRx pricing rollout effect on Novartis core margin through 2026. Shows whether direct-to-patient pricing compresses margins toward the 25% risk line.
Key numbers
- $54.5B net sales, FY2025, up 8% constant currency
- Avidity Biosciences acquisition, about $12B
- Medicines reach roughly 300M people worldwide
Named risks
- 2026 patent cliff on Entresto, Promacta, Tasigna causing H1 2026 sales decline.
- US MFN pricing and TrumpRx direct-to-patient regime compressing net US drug prices and margins.
- Integration risk on $12B Avidity and pending $1.5B Myricx acquisitions over 2 to 3 years.
- Ongoing Hatch-Waxman patent litigation across multiple generic manufacturers on Entresto.
- Q1 2026 EPS miss ($1.99 vs $2.11 consensus) signals near-term earnings volatility.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Roche | losing to | Roche overtook Novartis for 5th place in global pharma-sales rankings after Sandoz spin-off, per Citeline, March 2025 |
| Sandoz | contesting | Former Sandoz unit, now independent since Oct 2023, files generic challenges against Novartis patents like Entresto |
| Generic manufacturers (MSN, Alembic, Mylan/Viatris) | losing to | June 2026 non-infringement ruling opened partial generic competition to Entresto |
| Isomorphic Labs | contesting | Novartis is a named partner backing Isomorphic's AI drug-discovery platform alongside Chai Discovery, as of 2026 |
| Pfizer | losing to | Pfizer led 2024 pharma-sales rankings, ahead of Novartis, per Citeline March 2025 |
Questions people ask
- Is Novartis profitable in 2026?
- Yes. Novartis reported FY2025 core operating income of $21.9B on $54.5B net sales (40.1% core margin) and $17.6B free cash flow, per its Feb 4, 2026 results release. Q1 2026 revenue dipped 0.9% YoY to $13.52B amid patent-cliff erosion, but management guides a H2 2026 rebound.
- Could AI replace Novartis?
- No. Novartis's moat rests on patents, FDA approvals, global manufacturing, and payer relationships that AI cannot shortcut. It uses AI as a tool, partnering with Chai Discovery (July 13, 2026) and Isomorphic Labs for antibody/molecule design, but trials, approval, and distribution remain human-regulated bottlenecks.
- Who is Novartis's biggest competitor?
- Roche overtook Novartis for 5th place in global pharma-sales rankings after the October 2023 Sandoz spin-off shrank Novartis's reported scale, per Citeline (March 2025). Other major rivals include Pfizer, Merck, AstraZeneca, J&J, and AbbVie across oncology and immunology.
- Is Novartis facing layoffs in 2026?
- Headcount is roughly stable, not shrinking sharply. Novartis had 75,267 full-time employees as of Dec 31, 2025, down just 0.81% from 75,883 in 2024 (Statista, Feb 2026), well below pre-2023 levels of over 100,000 before the Sandoz spin-off.
- Is Novartis a safe company to join in 2026?
- Largely yes. Novartis posted $54.5B net sales and $17.6B free cash flow in FY2025 (reported Feb 4, 2026), and is investing $23B over five years in US R&D and manufacturing per its December 2025 government pricing deal, though 2026 revenue faces its largest-ever patent cliff.
- Who owns Novartis?
- Novartis AG is a publicly traded, widely held Swiss company with no controlling parent, listed as NOVN on the SIX Swiss Exchange and NVS on NYSE. Market cap was roughly CHF 238.5 billion (Swiss listing) as of July 20, 2026.
Timeline
- 2026-07-13Novartis announces AI antibody-design collaboration with Chai Discovery, access to Chai-3 model
- 2026-07-06Novartis agrees to acquire Myricx Bio for up to $1.5B for ADC payload platform
- 2026-06-11Novartis v. Alembic/MSN ruling opens partial generic competition to Entresto
- 2026-02-27Novartis completes ~$12B acquisition of Avidity Biosciences for RNA/AOC platform
- 2026-02-04Novartis reports FY2025: $54.5B net sales, 40.1% core margin, $17.6B free cash flow
- 2025-12-19Novartis and US government reach most-favored-nation drug pricing agreement
- 2023-10Sandoz generics/biosimilars unit divested as independent listed company
- 1996-12Novartis AG created
Head to head
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Novartis delivered high single-digit sales growth achieved 40% core margin and further advanced pipeline 2025 (2026-02-04)
- Novartis Pharmaceuticals in the U.S.
- Top 12 Pharma: Pfizer Tops the Leaderboard Again (2025-03-28)
- gurufocus.com (2026-07-20)
- Novartis (NVS) Expected to Post Earnings on Tuesday (2026-07-14)
- Novartis successfully completes acquisition of Avidity Biosciences (2026-02-27)
- NVS Q2 2026 Earnings Report (2026-07-06)
- Novartis AG (NVS) Earnings Dates, Call Summary & Reports (2026-07-14)
- Novartis (NVS) Earnings Date and Reports 2026 (2026-07-16)
- Novartis v. Alembic & MSN: Valsartan/Sacubitril Patent Dispute (2026-06-11)
- Novartis full-time employees number 2025 (2026-02-10)
- Novartis and US government reach agreement lowering drug prices US (2025-12-22)